Early progression of disease as a predictor of survival in chronic lymphocytic leukemia
Inhye E. Ahn(Dana-Farber Cancer Institute), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), David L. Grinblatt(NorthShore University HealthSystem), E. Dawn Flick, Pavel Kiselev, Charles M. Farber(Morristown Medical Center), Matthew S. Davids(Dana-Farber Cancer Institute), Anthony R. Mato(Memorial Sloan Kettering Cancer Center), Arlene S. Swern, Chadi Nabhan(University of Chicago), Neil E. Kay(Mayo Clinic), Kristen Sullivan, Nicole Lamanna(Memorial Sloan Kettering Cancer Center)
Cited by 13
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k